Cover Image
市場調查報告書

藥物遞送用輸液系統的全球市場:醫療設備的開發平台評估

Drug Delivery Infusion Systems - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 363396
出版日期 內容資訊 英文 311 Pages
訂單完成後即時交付
價格
Back to Top
藥物遞送用輸液系統的全球市場:醫療設備的開發平台評估 Drug Delivery Infusion Systems - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年10月01日 內容資訊: 英文 311 Pages
簡介

本報告提供全球藥物遞送用輸液設備的市場上之主要開發中產品及其臨床實驗的進展調查,再彙整產品功能·特性比較分析 (臨床實驗的各進展階段) ,以及主要企業簡介及代表性產品,近來的市場動靜 (業績報告·資本交易趨勢等) 資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 藥物遞送用輸液系統概要

第3章 臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各領域
  • 開發中產品:各地區
  • 開發中產品:各法規途徑
  • 開發中產品:推算各認證時期
  • 開發中產品:現在進行中的臨床實驗

第4章 臨床實驗中的開發中產品:各企業

  • 藥物遞送用輸液系統的企業:各臨床實驗階段的開發中產品
  • 藥物遞送用輸液系統:各臨床實驗階段的開發中產品

第5章 藥物遞送用輸液系統市場:企業·產品概要

  • 410 Medical Innovation, LLC
    • 開發中產品及進行中的臨床實驗概要
  • Acuros GmbH
  • AktiVax Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Anesthesia Safety Products, LLC
  • AngioDynamics, Inc.
  • Automedics Medical Systems
  • Baxter International Inc.
  • BioCardia, Inc.
  • Debiotech S.A.
  • Delpor, Inc.
  • Edwards Lifesciences Corporation
  • Eksigent Technologies, LLC
  • Eli Lilly and Company
  • Flowonix Medical, Inc.
  • FluidSynchrony, LLC
  • Fluonic, Inc. Company
  • Fresenius Kidney Care
  • Imagnus Biomedical Inc.
  • Innovfusion Pte. Ltd.
  • Intarcia Therapeutics, Inc.
  • IRadimed Corporation
  • Ivenix, Inc.
  • LifeMedix, LLC
  • Lynntech, Inc.
  • Medallion Therapeutics, Inc.
  • MedPrime Technologies Pvt. Ltd.
  • Mercator MedSystems, Inc.
  • Nano Precision Medical
  • NexGen Medical Systems, Inc.
  • Nipro
  • Owen Mumford Limited
  • Pavmed Inc
  • PRO-IV Medical Ltd.
  • Ratio, Inc.
  • Rice University
  • SteadyMed Therapeutics, Inc.
  • StnDrd Infusion
  • Tel Aviv University
  • Terumo Corporation
  • ToucheMedical Ltd.
  • Unilife Corporation
  • University of Minnesota
  • University of Southern California

第6章 藥物遞送用輸液系統市場:目前的趨勢 (全72件)

第7章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0472EPD

GlobalData's Medical Devices sector report, "Drug Delivery Infusion Systems - Medical Devices Pipeline Assessment, 2017" provides an overview of Drug Delivery Infusion Systems currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Drug Delivery Infusion Systems pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Drug Delivery Infusion Systems under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Drug Delivery Infusion Systems and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Drug Delivery Infusion Systems under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 8
  • 1.2 List of Figures 12

2 Introduction 13

  • 2.1 Drug Delivery Infusion Systems Overview 13

3 Products under Development 15

  • 3.1 Drug Delivery Infusion Systems - Pipeline Products by Stage of Development 15
  • 3.2 Drug Delivery Infusion Systems - Pipeline Products by Segment 16
  • 3.3 Drug Delivery Infusion Systems - Pipeline Products by Territory 17
  • 3.4 Drug Delivery Infusion Systems - Pipeline Products by Regulatory Path 18
  • 3.5 Drug Delivery Infusion Systems - Pipeline Products by Estimated Approval Date 19
  • 3.6 Drug Delivery Infusion Systems - Ongoing Clinical Trials 20

4 Drug Delivery Infusion Systems - Pipeline Products under Development by Companies 21

  • 4.1 Drug Delivery Infusion Systems Companies - Pipeline Products by Stage of Development 21
  • 4.2 Drug Delivery Infusion Systems - Pipeline Products by Stage of Development 24

5 Drug Delivery Infusion Systems Companies and Product Overview 26

  • 5.1 410 Medical Inc Company Overview 26
  • 5.2 Acuros GmbH Company Overview 27
  • 5.3 Adept Medical Ltd Company Overview 28
  • 5.4 AktiVax Inc. Company Overview 29
  • 5.5 Alnylam Pharmaceuticals Inc Company Overview 30
  • 5.6 AngioDynamics Inc Company Overview 31
  • 5.7 Automedics Medical Systems Inc (Inactive) Company Overview 34
  • 5.8 Baxter International Inc Company Overview 35
  • 5.9 Becton Dickinson and Co Company Overview 36
  • 5.10 BioCardia Inc Company Overview 37
  • 5.11 BioQ Pharma Inc Company Overview 40
  • 5.12 ClearLine MD Company Overview 43
  • 5.13 Debiotech SA Company Overview 44
  • 5.14 Edwards Lifesciences Corp Company Overview 45
  • 5.15 Eksigent Technologies LLC Company Overview 46
  • 5.16 Elcam Medical Company Overview 48
  • 5.17 Eli Lilly and Co Company Overview 49
  • 5.18 EryDel SPA Company Overview 50
  • 5.19 Flowonix Medical Inc Company Overview 53
  • 5.20 FluidSynchrony, LLC Company Overview 57
  • 5.21 Fluonic, Inc. Company Overview 58
  • 5.22 Fresenius Kidney Care Company Overview 59
  • 5.23 Hospira Inc Company Overview 60
  • 5.24 Imagnus Biomedical Inc. Company Overview 61
  • 5.25 Innovfusion Pte. Ltd. Company Overview 62
  • 5.26 Intarcia Therapeutics Inc Company Overview 65
  • 5.27 IRadimed Corp Company Overview 68
  • 5.28 Ivenix Inc Company Overview 69
  • 5.29 LifeMedix, LLC Company Overview 70
  • 5.30 Lynntech Inc Company Overview 71
  • 5.31 Massachusetts Institute of Technology Company Overview 72
  • 5.32 Medallion Therapeutics, Inc. Company Overview 73
  • 5.33 Medical Device Creations Ltd. Company Overview 74
  • 5.34 MedPrime Technologies Pvt. Ltd. Company Overview 75
  • 5.35 Medtronic plc Company Overview 76
  • 5.36 Nano Precision Medical Inc Company Overview 77
  • 5.37 NexGen Medical Systems Inc Company Overview 78
  • 5.38 Nipro Corp Company Overview 79
  • 5.39 Owen Mumford Ltd Company Overview 80
  • 5.40 Pavmed Inc Company Overview 81
  • 5.41 PRO-IV Medical Ltd Company Overview 82
  • 5.42 Ratio Inc Company Overview 83
  • 5.43 Rice University Company Overview 84
  • 5.44 SC Pharmaceuticals Inc Company Overview 85
  • 5.45 SteadyMed Therapeutics Inc Company Overview 86
  • 5.46 StnDrd Infusion Corporation Company Overview 89
  • 5.47 Surefire Medical Inc Company Overview 91
  • 5.48 Tandem Diabetes Care Inc Company Overview 95
  • 5.49 Terumo Corp Company Overview 96
  • 5.50 ToucheMedical Ltd. Company Overview 98
  • 5.51 Turnpoint Medical Devices Inc Company Overview 99
  • 5.52 Unilife Corporation Company Overview 100
  • 5.53 University of Minnesota Company Overview 101
  • 5.54 University of Southern California Company Overview 102
  • 5.55 vTitan Corporation Pvt Ltd Company Overview 103

6 Drug Delivery Infusion Systems- Recent Developments 105

  • 6.1 Sep 15, 2017: New Intarcia Study Evaluates Optimal Way to Switch from Daily Liraglutide Injections to ITCA 650 in Patients with Type 2 Diabetes 105
  • 6.2 Sep 11, 2017: MPSC Achieves Substantial Growth in 1H 2017 Net Profit Increases 272.4% YOY 106
  • 6.3 Sep 08, 2017: Fresenius Kabi marks 20-year anniversary of Friedberg production site - Logistics center expansion planned 107
  • 6.4 Sep 07, 2017: Lilly Takes Steps To Streamline Business, Invest In New Medicines And Drive Growth 108
  • 6.5 Sep 05, 2017: RMS Receives FDA Clearance for 510(k) 109
  • 6.6 Aug 31, 2017: Admedus Financial Results For The Year Ended 30 June 2017 110
  • 6.7 Aug 30, 2017: Smiths Medical Receives FDA 510(k) Clearance on Wireless Ambulatory Infusion Pump 112
  • 6.8 Aug 30, 2017: Ablative Solutions Announces Presentation at the Baird Global Healthcare Conference 113
  • 6.9 Aug 24, 2017: Tandem Diabetes Care Announces Issuance of Patent Related to Remote Bolus Feature for Medical Infusion Pumps 113
  • 6.10 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 114
  • 6.11 Aug 15, 2017: Changes in Novo Nordisk Executive Management 116
  • 6.12 Aug 14, 2017: MicroPort Lifesciences Hosts GnRH Pump Treatment Symposium 117
  • 6.13 Aug 14, 2017: ConvaTec appoints two Non-Executive Directors 118
  • 6.14 Aug 14, 2017: PAVmed Reports Second Quarter 2017 Financial Results 119
  • 6.15 Aug 11, 2017: MPSC Issues Positive Profit Alert for 2017 1H Net Profit Expected to Increase 261% 120
  • 6.16 Aug 11, 2017: SteadyMed Reports Second Quarter 2017 Financial Results and Provides Corporate Update 120
  • 6.17 Aug 09, 2017: Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 122
  • 6.18 Aug 09, 2017: Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity 123
  • 6.19 Aug 08, 2017: DURECT Announces Second Quarter 2017 Financial Results and Provides Corporate Update 124
  • 6.20 Aug 03, 2017: ConvaTec Group: Board Changes 126
  • 6.21 Aug 03, 2017: ConvaTec Group First Half 2017 Results 127
  • 6.22 Aug 03, 2017: Teleflex Reports Second Quarter 2017 Results 128
  • 6.23 Aug 02, 2017: Cardinal Health Reports Q4 and Fiscal 2017 Results, Provides 2018 Guidance 130
  • 6.24 Aug 02, 2017: Alimera Sciences Reports Second Quarter 2017 Financial Results 131
  • 6.25 Aug 01, 2017: RMS Medical Products Closes Four-Month Period Ending June 30, 2017 with Double-Digit Percentage Growth 133
  • 6.26 Aug 01, 2017: Fresenius confirms its guidance after a strong second quarter with double-digit sales and earnings growth 135
  • 6.27 Jul 31, 2017: SteadyMed Appoints Jeff Myers M.D. Ph.D. Vice President of Medical Affairs 137
  • 6.28 Jul 28, 2017: IRADIMED Announces Second Quarter 2017 Financial Results 138
  • 6.29 Jul 26, 2017: Baxter Reports Second-Quarter 2017 Results and Provides Updated Financial Outlook for 2017 and 2020 140
  • 6.30 Jul 25, 2017: Lilly Reports Second-Quarter Results 142
  • 6.31 Jul 25, 2017: 3M Delivers Second-Quarter Sales of $7.8 Billion and Earnings of $2.58 per Share; Company Updates Its 2017 Outlook 146
  • 6.32 Jul 24, 2017: MicroPort Lifesciences Attends 2017 CEA Annual Meeting 148
  • 6.33 Jul 24, 2017: MicroPort Attends EUROPACE-CARDIOSTIM 2017 149
  • 6.34 Jul 21, 2017: Fresenius appoints Rachel Empey as Chief Financial Officer 149
  • 6.35 Jul 18, 2017: AngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results 150
  • 6.36 Jul 17, 2017: Baxter Appoints Cathy R. Smith to its Board 152
  • 6.37 Jul 12, 2017: Fresenius Medical Care successfully amends and extends its credit agreement, ahead of schedule 152
  • 6.38 Jul 07, 2017: MPSC New COO Glendy Wang on Board 152
  • 6.39 Jul 06, 2017: Fresenius Kabi expands production site in Portugal 153
  • 6.40 Jul 03, 2017: Cardiome's Partner SteadyMed Submits U.S. New Drug Application for TREVYENT for the Treatment of Pulmonary Arterial Hypertension 153
  • 6.41 Jul 03, 2017: Silence Therapeutics: Issue of claim in the UK High Courts 153

7 Appendix 307

  • 7.1 Methodology 307
  • 7.2 About GlobalData 310
  • 7.3 Contact Us 310
  • 7.4 Disclaimer 310

List of Tables

1.1 List of Tables

  • Table 1: Drug Delivery Infusion Systems - Pipeline Products by Stage of Development 16
  • Table 2: Drug Delivery Infusion Systems - Pipeline Products by Segment 17
  • Table 3: Drug Delivery Infusion Systems - Pipeline Products by Territory 18
  • Table 4: Drug Delivery Infusion Systems - Pipeline Products by Regulatory Path 19
  • Table 5: Drug Delivery Infusion Systems - Pipeline Products by Estimated Approval Date 20
  • Table 6: Drug Delivery Infusion Systems - Ongoing Clinical Trials 21
  • Table 7: Infusion Systems Companies - Pipeline Products by Stage of Development 22
  • Table 8: Drug Delivery Infusion Systems - Pipeline Products by Stage of Development 25
  • Table 9: 410 Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 27
  • Table 10: LifeFlow Rapid Infusion Device - Severe Hemorrhage - Product Status 27
  • Table 11: LifeFlow Rapid Infusion Device - Severe Hemorrhage - Product Description 27
  • Table 12: Acuros GmbH Pipeline Products & Ongoing Clinical Trials Overview 28
  • Table 13: Disposable Micropump - Product Status 28
  • Table 14: Disposable Micropump - Product Description 28
  • Table 15: Adept Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 29
  • Table 16: Adept IVO - Product Status 29
  • Table 17: Adept IVO - Product Description 29
  • Table 18: AktiVax Inc. Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 19: Immunoject - Product Status 30
  • Table 20: Immunoject - Product Description 30
  • Table 21: Alnylam Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 22: ALN-HTT Infusion System - Product Status 31
  • Table 23: ALN-HTT Infusion System - Product Description 31
  • Table 24: AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 25: BioFlo Portline Line Extension - Product Status 32
  • Table 26: BioFlo Portline Line Extension - Product Description 32
  • Table 27: Next Generation BioFlo Port - Product Status 33
  • Table 28: Next Generation BioFlo Port - Product Description 33
  • Table 29: Power Injectable Port - Product Status 33
  • Table 30: Power Injectable Port - Product Description 34
  • Table 31: Smart Port - Dual - Product Status 34
  • Table 32: Smart Port - Dual - Product Description 34
  • Table 33: Automedics Medical Systems Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 35
  • Table 34: AutoHep System - Product Status 35
  • Table 35: AutoHep System - Product Description 35
  • Table 36: Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 37: Infusion Pump - Product Status 36
  • Table 38: Infusion Pump - Product Description 36
  • Table 39: Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 40: BodyGuard Quadro - Product Status 37
  • Table 41: BodyGuard Quadro - Product Description 37
  • Table 42: BioCardia Inc Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 43: Helix Transendocardial Delivery System - Product Status 38
  • Table 44: Helix Transendocardial Delivery System - Product Description 38
  • Table 45: BioCardia Inc - Ongoing Clinical Trials Overview 39
  • Table 46: Helix Transendocardial Delivery System - A Multicentric Controlled Phase I / IIb Study Evaluating the Safety and the Efficacy of in Vitro Expanded Peripheral Blood CD34+ Stem Cells Output by the StemXpand Automated Process, and Injected in Patients with an Acute Myocardial Infarction and a Left Ventricle Ejection Fraction (LVEF) Remaining Below or Equal to 45% after PTCA and Stent(s) Implantation Versus Standard of Care 40
  • Table 47: Helix Transendocardial Delivery System - A Phase II, Randomized, Blinded, Study of the Safety and Efficacy of Transendocardial Injection of Allogeneic Human Mesenchymal Stem Cells (hMSCs) (20 Million or 100 Million Total MSCs) in Patients with Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction 40
  • Table 48: Helix Transendocardial Delivery System - Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial) 40
  • Table 49: BioQ Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 50: Pre-Filled Infusion System - Antibiotics - Product Status 41
  • Table 51: Pre-Filled Infusion System - Antibiotics - Product Description 41
  • Table 52: Pre-Filled Infusion System - Oncology - Product Status 42
  • Table 53: Pre-Filled Infusion System - Oncology - Product Description 42
  • Table 54: Propofol Pre-Filled Infusion System - Product Status 42
  • Table 55: Propofol Pre-Filled Infusion System - Product Description 43
  • Table 56: Ropivacaine ReadyFusOR - Product Status 43
  • Table 57: Ropivacaine ReadyFusOR - Product Description 43
  • Table 58: ClearLine MD Pipeline Products & Ongoing Clinical Trials Overview 44
  • Table 59: FloStat Infusion Pump System - Product Status 44
  • Table 60: FloStat Infusion Pump System - Product Description 44
  • Table 61: Debiotech SA Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 62: MIP Device - Product Status 45
  • Table 63: MIP Device - Product Description 45
  • Table 64: Edwards Lifesciences Corp Pipeline Products & Ongoing Clinical Trials Overview 46
  • Table 65: Integrated Semi-Closed Loop System - Product Status 46
  • Table 66: Integrated Semi-Closed Loop System - Product Description 46
  • Table 67: Eksigent Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 47
  • Table 68: External Drug Delivery System - Product Status 47
  • Table 69: External Drug Delivery System - Product Description 47
  • Table 70: Implantable Drug Delivery System - Product Status 48
  • Table 71: Implantable Drug Delivery System - Product Description 48
  • Table 72: Elcam Medical Pipeline Products & Ongoing Clinical Trials Overview 49
  • Table 73: Patch Pump - Product Status 49
  • Table 74: Patch Pump - Product Description 49
  • Table 75: Eli Lilly and Co Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 76: Drug Delivery System - Parkinson's Disease - Product Status 50
  • Table 77: Drug Delivery System - Parkinson's Disease - Product Description 50
  • Table 78: EryDel SPA Pipeline Products & Ongoing Clinical Trials Overview 51
  • Table 79: EryDex System - Product Status 51
  • Table 80: EryDex System - Product Description 51
  • Table 81: EryDel SPA - Ongoing Clinical Trials Overview 52
  • Table 82: EryDex System - Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telangiectasia 53
  • Table 83: Flowonix Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 54
  • Table 84: Implanted Drug Delivery System - Product Status 54
  • Table 85: Implanted Drug Delivery System - Product Description 54
  • Table 86: Prometra II Programmable Infusion System - Product Status 55
  • Table 87: Prometra II Programmable Infusion System - Product Description 55
  • Table 88: Flowonix Medical Inc - Ongoing Clinical Trials Overview 56
  • Table 89: Prometra II Programmable Infusion System - A Dose Ranging Pilot Study to Assess Intracerebroventricular (ICV) Delivery of Valproate in Subjects with Focal Seizures, with Temporal Lobe Onset with or without Secondary Generalization 57
  • Table 90: FluidSynchrony, LLC Pipeline Products & Ongoing Clinical Trials Overview 58
  • Table 91: FluidSync Pump - Product Status 58
  • Table 92: FluidSync Pump - Product Description 58
  • Table 93: Fluonic, Inc. Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 94: SURE+ - Product Status 59
  • Table 95: SURE+ - Product Description 59
  • Table 96: Fresenius Kidney Care Pipeline Products & Ongoing Clinical Trials Overview 60
  • Table 97: Intravenous 2008MeDS - Product Status 60
  • Table 98: Intravenous 2008MeDS - Product Description 60
  • Table 99: Hospira Inc Pipeline Products & Ongoing Clinical Trials Overview 61
  • Table 100: Smart Infusion Pump Integrated With Accelero Connect Software - Product Status 61
  • Table 101: Smart Infusion Pump Integrated With Accelero Connect Software - Product Description 61
  • Table 102: Imagnus Biomedical Inc. Pipeline Products & Ongoing Clinical Trials Overview 62
  • Table 103: DeltaFlow Infusion Regulator - Product Status 62
  • Table 104: DeltaFlow Infusion Regulator - Product Description 62
  • Table 105: Innovfusion Pte. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 63
  • Table 106: DIVA - Product Status 63
  • Table 107: DIVA - Product Description 63
  • Table 108: EPIVA - Product Status 64
  • Table 109: EPIVA - Product Description 64
  • Table 110: INTRAVA - Product Status 64
  • Table 111: INTRAVA - Product Description 65
  • Table 112: Intarcia Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 66
  • Table 113: ITCA 650 Osmotic Pump - Product Status 66
  • Table 114: ITCA 650 Osmotic Pump - Product Description 66
  • Table 115: Intarcia Therapeutics Inc - Ongoing Clinical Trials Overview 67
  • Table 116: ITCA 650 Osmotic Pump - A Phase IIIb, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients with Type 2 Diabetes 68
  • Table 117: ITCA 650 Osmotic Pump - An Open-label, Multi-center, Randomized, Phase IIIb Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients with Type 2 Diabetes Receiving Stable Doses of Liraglutide 68
  • Table 118: IRadimed Corp Pipeline Products & Ongoing Clinical Trials Overview 69
  • Table 119: Next-generation MRI IV Pump - Product Status 69
  • Table 120: Next-generation MRI IV Pump - Product Description 69
  • Table 121: Ivenix Inc Pipeline Products & Ongoing Clinical Trials Overview 70
  • Table 122: Ivenix Infusion Management System - Product Status 70
  • Table 123: Ivenix Infusion Management System - Product Description 70
  • Table 124: LifeMedix, LLC Pipeline Products & Ongoing Clinical Trials Overview 71
  • Table 125: STATfusion - Product Status 71
  • Table 126: STATfusion - Product Description 71
  • Table 127: Lynntech Inc Pipeline Products & Ongoing Clinical Trials Overview 72
  • Table 128: Disposable Drug Infusion Pump - Product Status 72
  • Table 129: Disposable Drug Infusion Pump - Product Description 72
  • Table 130: Massachusetts Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 73
  • Table 131: Compact Self-Powered Actuator - Product Status 73
  • Table 132: Compact Self-Powered Actuator - Product Description 73
  • Table 133: Medallion Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 74
  • Table 134: Medallion Infusion System - Product Status 74
  • Table 135: Medallion Infusion System - Product Description 74
  • Table 136: Medical Device Creations Ltd. Pipeline Products & Ongoing Clinical Trials Overview 75
  • Table 137: Infusion Pump - Product Status 75
  • Table 138: Infusion Pump - Product Description 75
  • Table 139: MedPrime Technologies Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 76
  • Table 140: InfuCheck - Product Status 76
  • Table 141: InfuCheck - Product Description 76
  • Table 142: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 77
  • Table 143: SynchroMed II+ - Product Status 77
  • Table 144: SynchroMed II+ - Product Description 77
  • Table 145: Nano Precision Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 78
  • Table 146: Nano Portal Capsule - Product Status 78
  • Table 147: Nano Portal Capsule - Product Description 78
  • Table 148: NexGen Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 79
  • Table 149: PeriCATH - Product Status 79
  • Table 150: PeriCATH - Product Description 79
  • Table 151: Nipro Corp Pipeline Products & Ongoing Clinical Trials Overview 80
  • Table 152: Pump For Venous Anesthesia Infusion - Product Status 80

List of Figures

1.2 List of Figures

  • Figure 1: Drug Delivery Infusion Systems - Pipeline Products by Stage of Development 16
  • Figure 2: Drug Delivery Infusion Systems - Pipeline Products by Segment 17
  • Figure 3: Drug Delivery Infusion Systems - Pipeline Products by Territory 18
  • Figure 4: Drug Delivery Infusion Systems - Pipeline Products by Regulatory Path 19
  • Figure 5: Drug Delivery Infusion Systems - Pipeline Products by Estimated Approval Date 20
  • Figure 6: Drug Delivery Infusion Systems - Ongoing Clinical Trials 21
Back to Top